Studies indicate that directing interventions towards ZBP1, caspases, NLRP3, RIPK1, and RIPK3 can trigger a robust anti-tumor immune response, facilitating the efficient eradication of cancer cells. This evidence concerns the gene ZBP1 and neoplasm.